	US 12,352,765 B2
	Compositions and methods of prognosis and classification for preeclampsia
Brice L. Gauilliere, Palo Alto, CA (US); Martin S. Angst, Stanford, CA (US); Nima Aghaeepour, Stanford, CA (US); David K. Stevenson, Palo Alto, CA (US); Xiaoyuan Han, Stanford, CA (US); and Mohammad S. Ghaemi, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Appl. No. 17/291,858
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
PCT Filed Nov. 14, 2019, PCT No. PCT/US2019/061504 § 371(c)(1), (2) Date May 6, 2021, PCT Pub. No. WO2020/102556, PCT Pub. Date May 22, 2020.
Claims priority of provisional application 62/767,957, filed on Nov. 15, 2018.
Prior Publication US 2022/0011319 A1, Jan. 13, 2022
Int. Cl. G01N 33/68 (2006.01)

CPC G01N 33/6893 (2013.01) [G01N 2333/46 (2013.01); G01N 2800/368 (2013.01)]

19 Claims

1. A method for treating an individual having a propensity to develop preeclampsia during pregnancy, comprising:

obtaining a cellular biological sample for analysis comprising immune cells from a patient during pregnancy from at least two timepoints during the pregnancy, wherein the timepoints are in first trimester and second trimester;

measuring single cell basal levels of pSTAT5 in CD4⁺T cells in the biological sample at the at least two timepoints;

determining whether the single cell basal level of pSTAT5 in CD4⁺T cells has decreased between a first trimester sample and a second trimester sample during the pregnancy, indicating a propensity to develop preeclampsia; and

providing an assessment of the patient's prognosis for propensity to develop preeclampsia; and

treating the individual assessed as having a propensity to develop preeclampsia by administering aspirin or IL-2.